SynthesisJournal of cellular and molecular medicine2025
Circulating miR-542-3p as a Prognostic Marker for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Synthesis in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Circulating miR-542-3p as a Prognostic Marker for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.Journal of cellular and molecular medicine · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, particularly in Asia. Despite therapeutic advancements, the prognosis of HCC remains poor. MicroRNAs have emerged as potential biomarkers for HCC prognosis and therapeutic response. This systematic review and meta-analysis examined the association between circulating miR-542-3p levels and HCC progression. Seven studies on HCC and miR-542-3p were selected for the meta-analysis. miR-542-3p showed significant diagnostic potential for HCC prognosis and therapeutic evaluation. Two independent researchers performed data extraction and used the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) method to assess the quality and risk of bias of the included studies. After the meta-analysis, human miRNA pattern analysis was conducted using the miRBase database, and the expression of miR-542-3p was confirmed based on the results obtained from the human miRNA profile in the tissue atlas database. miR-542-3p has been shown to have significant diagnostic potential for HCC prognosis and therapeutic evaluation. The pooled sensitivity was 0.79 (95% CI, 0.75-0.83), while the pooled specificity was 0.34 (95% CI, 0.29-0.40). The diagnostic odds ratio was 7.2, with an AUC of 0.806, indicating moderate diagnostic accuracy. Network analysis in miRBase links miR-542-3p to liver function, and its location on the X chromosome allows its expression in both sexes, making it widely applicable for the diagnosis of HCC. Thus, miR-542-3p has potential as a prognostic biomarker for HCC, with prospects for integration into therapeutic strategies. Future studies should explore the combination of this with targeted therapies to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.